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Introduction
Acute hypocalcaemia can be life threatening, necessitating 
urgent treatment. In severe cases, intravenous calcium 
forms the mainstay of initial therapy, but it is essential 
to ascertain the underlying cause and commence specific 
therapy as early as possible. This guideline aims to take 
the non-specialist through the initial phase of assessment 
and management.
Clinical presentation
Potential causes
Symptoms of hypocalcaemia typically develop 
when adjusted serum calcium levels fall below 
~1.9 mmol/L. However, this threshold varies greatly 
and is dependent on the rate of fall.
Symptoms and signs of hypocalcaemia include:
 • Peri-oral and digital paraesthesiae
 • Positive Trousseau’s and Chvostek’s signs
 • Tetany and carpopedal spasm
 • Laryngospasm
 • ECG changes (prolonged QT interval) and  
arrhythmia
 • Seizure
The most common cause of acute symptomatic 
hypocalcaemia in hospital practice is disruption of 
parathyroid gland function due to total thyroidectomy. 
Hypocalcaemia may be temporary or permanent.
Other causes include:
 • Following selective parathyroidectomy (hypocalcaemia 
is usually transient and mild)
 • Severe vitamin D deficiency
 • Mg2+ deficiency (consider PPI-associated hypo-
magnesaemia)
 • Cytotoxic drug-induced hypocalcaemia
 • Pancreatitis, rhabdomyolysis and large volume blood 
transfusions
Investigations
 • Serum calcium (adjusted for albumin)
 • Phosphate
 • Parathyroid hormone (PTH)
 • Urea and electrolytes
 • Vitamin D
 • Magnesium
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Management
‘Mild’ hypocalcaemia
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‘Mild’ hypocalcaemia: asymptomatic; serum calcium 
>1.9 mmol/L.
 • Commence oral calcium supplements such as Sandocal 
1000, 2 tablets BD (Alternatives include Adcal 3 tablets 
BD, Cacit 4 tablets BD, or Calcichew Forte 2 tablets BD).
 • If post-thyroidectomy and patient asymptomatic, 
repeat calcium 24 h later:
 – When adjusted calcium is >2.1 mmol/L, patient may 
be discharged and recheck calcium within 1 week.
 – If serum calcium remains between 1.9 and 
2.1 mmol/L increase Sandocal 1000 to three BD
 – If patient remains in mild hypocalcaemic range 
beyond 72 h post-operatively despite calcium supple-
mentation, start alfacalcidol 0.25 micrograms/day 
(calcitriol may also be used) with close monitoring 
(see ‘Long-term follow-up’ below)
 • If vitamin D deficiency is the cause, commence vitamin 
D supplementation: load with ~300,000 units of 
cole- or ergocalciferol over ~6–10 weeks
 • If hypomagnesaemia-related, stop any precipitating drug 
and administer i.v. Mg2+, 24 mmol/24 h, made up as 6 g 
of MgSO4 (30 mL of 20%, 800 mmol/L, MgSO4) in 500 mL 
Normal saline or 5% dextrose. Monitor serum Mg2+ and 
aim to achieve normal serum magnesium level
 • If other cause of hypocalcaemia, treat underlying 
condition.
Severe hypocalcaemia
Severe hypocalcaemia: serum calcium <1.9 mmol/L 
and/or symptomatic at any level below reference range.
 • This is a medical emergency
 • Administer i.v. calcium gluconate
 • Initially, give 10–20 mL 10% calcium gluconate in 
50–100 mL of 5% dextrose i.v. over 10 min with ECG 
monitoring. This can be repeated until the patient 
is asymptomatic. It should be followed up with a 
calcium gluconate infusion as follows:
 – Dilute 100 mL of 10% calcium gluconate (10 vials) 
in 1 L of Normal saline or 5% dextrose and infuse at 
50–100 mL/h. (Calcium chloride can be used as an 
alternative to calcium gluconate, but it is more irritant 
to veins and should only be given via a central line)
 – Titrate the rate of infusion to achieve 
normocalcaemia and continue until treatment of 
the underlying cause has taken effect
 • Treat the underlying cause; in post-operative hypo-
calcaemia and other cases of hypoparathyroidism, this 
consists of alfacalcidol or calcitriol therapy. Starting doses 
should be approximately 0.25–0.5 micrograms per day
 – 1-alpha hydroxylated vitamin D metabolites are 
potent causes of hypercalcaemia. Frequent blood 
tests are required in stabilisation phase of treatment
 – alfacalcidol can be administered (at equivalent doses) 
intravenously if there are concerns about absorbtion 
or difficulties with oral drug administration
 – NB: Large volume calcium infusions should not 
be used in patients with end stage renal failure or 
who are on dialysis. Guidance on management of 
hypocalcaemia in these patients is available in the 
NKF KDOQI guidelines (http://www2.kidney.org/
professionals/KDOQI/guidelines_bone/Guide14.htm)
 • Vitamin D deficiency or hypomagnesaemia should be 
treated as described above
Hazards of i.v. calcium administration
Uncommon, but include local thrombophlebitis, 
cardiotoxicity, hypotension, calcium taste, flushing, 
nausea, vomiting and sweating. Patients with cardiac 
arrhythmias or on digoxin therapy need continuous ECG 
monitoring during i.v. calcium replacement.
Long-term follow-up
For patients commenced on alfacalcidol or calcitriol, 
monitoring of adjusted serum calcium levels should 
initially be performed approximately one week post 
discharge, then if satisfactory at one, three and then six 
months. Follow-up by a specialist with an interest in 
calcium disorders is recommended.
Disclaimer
The document should be considered as a guideline only; it is not intended 
to determine an absolute standard of medical care. The doctors concerned 
must make the management plan for an individual patient. 
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